{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:27:15Z","timestamp":1793798835928,"version":"4.6.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["NCT03370263"],"award-info":[{"award-number":["NCT03370263"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess safety of belimumab in Japanese patients with systemic lupus erythematosus in real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This all-case post-marketing surveillance study included patients initiating belimumab between December 2017 and October 2018. To evaluate safety, patients were observed for up to 52\u00a0weeks. In main population, baseline risk factors for serious infection were assessed by multivariate analysis. Exploratory risk factor analysis for depression\/suicidal ideation\/suicide attempt was conducted in expanded population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1177 patients (main population), incidence rates per 100 person-years of serious adverse events and adverse events of special interest were: serious adverse events, 28.4; serious infection, 8.8; depression\/suicidal ideation\/suicide attempt, 1.3; malignant tumour, 0.7; serious hypersensitivity, 0.7. Male sex, any comorbidity, and glucocorticoid dose at baseline were independent risk factors for serious infection. In an exploratory analysis, comorbidity of depression\/suicidal ideation\/suicide attempt at belimumab initiation was an associated characteristic factor for the new occurrence\/worsening depression\/suicidal ideation\/suicide attempt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No new safety concerns were identified compared with previously reported data and current belimumab labelling. The incidence rate of depression\/suicidal ideation\/suicide attempt was similar to that previously reported for patients with systemic lupus erythematosus. Patients with risk factors for serious infection and depression\/suicidal ideation\/suicide attempt should be carefully monitored.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag066","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:26:43Z","timestamp":1786706803000},"page":"950-963","source":"Crossref","is-referenced-by-count":1,"title":["Safety of intravenous and subcutaneous belimumab in Japanese patients with systemic lupus erythematosus: Final analysis of data from an all-case post-marketing surveillance study"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9085-5250","authenticated-orcid":false,"given":"Nami","family":"Okamoto","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Osaka Rosai Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5657-962X","authenticated-orcid":false,"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology, and Nephrology, Hokkaido University , Sapporo, Hokkaido ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center , Niigata ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobunori","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Aichi Medical University , Nagakute, Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-2954","authenticated-orcid":false,"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ueno Dialysis Clinic , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Center for Rheumatic Diseases, Mie University Hospital , Mie ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2209-8454","authenticated-orcid":false,"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Nishida","sequence":"additional","affiliation":[{"name":"Locomotive Pain Center, Faculty of Medical Development Field, Okayama University , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Matsuno","sequence":"additional","affiliation":[{"name":"Matsuno Clinic for Rheumatic Diseases , Toyama City, Toyama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Asamura","sequence":"additional","affiliation":[{"name":"GSK K.K. Japan , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Koyano","sequence":"additional","affiliation":[{"name":"GSK K.K. Japan , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Hayashi","sequence":"additional","affiliation":[{"name":"GSK K.K. Japan , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"GSK K.K. Japan , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Noda","sequence":"additional","affiliation":[{"name":"GSK K.K. Japan , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kaneko","sequence":"additional","affiliation":[{"name":"GSK K.K. Japan , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Saito","sequence":"additional","affiliation":[{"name":"GSK K.K. Japan , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3052-787X","authenticated-orcid":false,"given":"Michiaki","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine , Yamagata ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9210-9414","authenticated-orcid":false,"given":"Sakae","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Saitama Medical University , Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026110407415398800_ref1","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026110407415398800_ref2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/rheumatology\/kep062","article-title":"Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years","volume":"48","author":"Chambers","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2026110407415398800_ref3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/rheumatology\/kez516","article-title":"Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort","volume":"59","author":"Segura","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026110407415398800_ref4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acr.20648","article-title":"Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort","volume":"64","author":"Urowitz","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026110407415398800_ref5","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2026110407415398800_ref6","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/toxsci\/kfj148","article-title":"Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects","volume":"91","author":"Halpern","year":"2006","journal-title":"Toxicol Sci"},{"key":"2026110407415398800_ref7","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1177\/0961203313502571","article-title":"Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes","volume":"22","author":"Gonz\u00e1lez","year":"2013","journal-title":"Lupus"},{"key":"2026110407415398800_ref8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/acr.20683","article-title":"Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality","volume":"64","author":"Jakes","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026110407415398800_ref9","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S2665-9913(21)00009-6","article-title":"The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus","volume":"3","author":"Mok","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026110407415398800_ref10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026110407415398800_ref11","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2026110407415398800_ref12","author":"Benlysta","year":"2025"},{"key":"2026110407415398800_ref13","author":"EMA","year":"2025"},{"key":"2026110407415398800_ref14","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 years of belimumab experience: what have we learnt?","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"2026110407415398800_ref15","author":"GSK"},{"key":"2026110407415398800_ref16","author":"GSK.K.K Japan","year":"2025"},{"key":"2026110407415398800_ref17","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2026110407415398800_ref18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"2026110407415398800_ref19","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026110407415398800_ref20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026110407415398800_ref21","doi-asserted-by":"crossref","first-page":"e001629","DOI":"10.1136\/rmdopen-2021-001629","article-title":"Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea","volume":"7","author":"Tanaka","year":"2021","journal-title":"RMD Open"},{"key":"2026110407415398800_ref22","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2665-9913(20)30355-6","article-title":"Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial","volume":"3","author":"Sheikh","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026110407415398800_ref23","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40744-020-00243-2","article-title":"Real-world effectiveness of belimumab in the treatment of systemic lupus erythematosus: pooled analysis of multi-country data from the OBSErve Studies","volume":"7","author":"Collins","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2026110407415398800_ref24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3899\/jrheum.2025-0390.PV258b","article-title":"Belimumab for the treatment of systemic lupus erythematosus in real world: a single-center study","volume":"52","author":"Calabuig","year":"2025","journal-title":"J Rheumatol"},{"key":"2026110407415398800_ref25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13075-024-03389-4","article-title":"Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study","volume":"26","author":"Su","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2026110407415398800_ref26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of Black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026110407415398800_ref27","doi-asserted-by":"crossref","first-page":"e001400","DOI":"10.1136\/lupus-2024-001400","article-title":"Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis","volume":"12","author":"Li","year":"2025","journal-title":"Lupus Sci Med"},{"key":"2026110407415398800_ref28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12026-025-09651-4","article-title":"Risk factors for infections in systemic lupus erythematosus: a meta-analysis","volume":"73","author":"Xuan","year":"2025","journal-title":"Immunol Res"},{"key":"2026110407415398800_ref29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/bioengineering12010059","article-title":"Impact of sex on infection risk in patients with systemic lupus erythematosus","volume":"12","author":"Borrelli","year":"2025","journal-title":"Bioengineering (Basel)"},{"key":"2026110407415398800_ref30","doi-asserted-by":"crossref","first-page":"9704","DOI":"10.1038\/s41598-019-46039-5","article-title":"Associated clinical factors for serious infections in patients with systemic lupus erythematosus","volume":"9","author":"Jung","year":"2019","journal-title":"Sci Rep"},{"key":"2026110407415398800_ref31","first-page":"704","article-title":"Risk factors for serious infections in inpatients with systemic lupus erythematosus","volume":"46","author":"Wang","year":"2021","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"2026110407415398800_ref32","author":"PMDA","year":"2025"},{"key":"2026110407415398800_ref33","author":"PMDA","year":"2025"},{"key":"2026110407415398800_ref34","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3899\/jrheum.140111","article-title":"Predictors of incident depression in systemic lupus erythematosus","volume":"41","author":"Huang","year":"2014","journal-title":"J Rheumatol"},{"key":"2026110407415398800_ref35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.berh.2017.09.013","article-title":"A review on SLE and malignancy","volume":"31","author":"Choi","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026110407415398800_ref36","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.semarthrit.2021.09.009","article-title":"Risk of malignancy in patients with systemic lupus erythematosus: systematic review and meta-analysis","volume":"51","author":"Clarke","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2026110407415398800_ref37","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1177\/09612033221131501","article-title":"Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival","volume":"31","author":"Kariniemi","year":"2022","journal-title":"Lupus"},{"key":"2026110407415398800_ref38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13256-025-05091-8","article-title":"Progressive multifocal leukoencephalopathy in rheumatoid arthritis and biological therapies: a case report and review of the literature","volume":"19","author":"Bergmans","year":"2025","journal-title":"J Med Case Rep"},{"key":"2026110407415398800_ref39","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.semarthrit.2020.06.004","article-title":"Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis of observational studies","volume":"50","author":"Yuan","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2026110407415398800_ref40","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.cpr.2007.02.005","article-title":"Risk for recurrence in depression","volume":"27","author":"Burcusa","year":"2007","journal-title":"Clin Psychol Rev"},{"key":"2026110407415398800_ref41","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1176\/ajp.148.10.1353","article-title":"Predictors of relapse into major depressive disorder in a nonclinical population","volume":"148","author":"Coryell","year":"1991","journal-title":"Am J Psychiatry"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag066\/70709157\/roag066.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/6\/950\/70709157\/roag066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/6\/950\/70709157\/roag066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:42:01Z","timestamp":1793796121000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/6\/950\/8766071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roag066","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,8,19]]}}}